Anti-migration stent

Abstract

A system for implanting a stent in a body lumen may include an elongate tubular member having a lumen extending therethrough, a stent configured to transition from a delivery configuration to a deployed configuration, and an adhesive structure configured to secure the stent to the body lumen in the deployed configuration. The stent may be disposed within the lumen of the elongate tubular member in the delivery configuration. The adhesive structure may be disposed within the lumen of the elongate tubular member adjacent to the stent in a substantially inactive state. The adhesive structure may be configured to adhere to the stent and the body lumen after the stent and adhesive structure are deployed from the lumen of the elongate tubular member into the body lumen.

Description

[Technical field]

[0001] FIELD OF THE DISCLOSURE The present disclosure relates to medical devices and methods of making and / or using medical devices. More particularly, the present disclosure relates to improved designs for endoprostheses or stents. [Background technology]

[0002] Stents, grafts, stent-grafts, and similar implantable medical devices (collectively referred to hereinafter as stents) are radially expandable or self-expanding endoprostheses, which are endovascular or endoscopic grafts that can be implanted transluminally, either percutaneously or endoscopically. Stents can be implanted in various body lumens or vessels, such as the vasculature, urinary tract, bile duct, gastrointestinal tract, airways, etc. Stents can be used to open narrowed body lumens. Stents can be used to reinforce body vessels and to prevent restenosis after angioplasty in the vasculature. They can be self-expanding, mechanically expanding, or hybrid expanding. Generally, self-expanding stents are mounted on a delivery device consisting of two tubes. Stents are delivered by sliding the outer tube to expose and release the stent.

[0003] A stent is typically a tubular member that, when deployed at a treatment site, is radially expandable from a reduced diameter configuration to an expanded configuration for delivery through a patient's body lumen. Stents can be formed from tubular members on which a pattern is subsequently formed by etching or cutting material from the tubular member, or can be made from wires or filaments using techniques such as braiding, knitting, or weaving. Desirable stent characteristics include sufficient flexibility to allow the stent to conform to tortuous body lumens during delivery, as well as sufficient stiffness to resist migration once deployed at a treatment site.

[0004] In some stents, the compressibility and flexibility properties that aid in stent delivery may also tend to cause the stent to migrate from its original deployed position. Stent migration affects many endoscopic stents, including esophageal, duodenal, colonic, pancreatic, biliary, and airway stents. It is therefore desirable to provide a stent configuration that resists migration after deployment.

[0005] Several techniques have been developed to prevent stent migration, including adding barbs and flares to the stent itself, or using clips or sutures to attach the stent to the vessel wall, however, there remains a need for improved stents that resist migration. Summary of the Invention

[0006] In one example, a system for implanting a stent in a body lumen can include an elongate tubular member having a lumen extending therethrough, a stent configured to transition from a delivery configuration to a deployed configuration, and an adhesive structure configured to secure the stent to the body lumen in the deployed configuration. The stent can be disposed within the lumen of the elongate tubular member in the delivery configuration. The adhesive structure can be disposed within the lumen of the elongate tubular member adjacent to the stent in a substantially inactive state. The adhesive structure can be configured to adhere to the stent and the body lumen after the stent and adhesive structure are deployed from the lumen of the elongate tubular member into the body lumen.

[0007] Additionally or alternatively to any of the embodiments described herein, the adhesive structure may be unsecured to the stent within the lumen of the elongate tubular member. In addition or as an alternative to any of the embodiments described herein, the adhesive structure includes adhesive elements that are activated upon deployment within the body lumen.

[0008] In addition or as an alternative to any of the embodiments described herein, the adhesive element is pressure sensitive. Additionally or alternatively to any of the embodiments described herein, the adhesive structure is disposed radially outward of the stent within the lumen of the elongate tubular member.

[0009] In addition or as an alternative to any of the embodiments described herein, after the stent and adhesive structure are deployed within the body lumen, the stent exerts a radially outward force on the adhesive structure and the body lumen.

[0010] In addition or as an alternative to any of the embodiments described herein, the outward radial force enhances adhesion between the stent and the adhesion structure, and between the adhesion structure and the body lumen. In addition, or as an alternative to any of the embodiments described herein, the adhesive structure extends circumferentially around a majority of the circumference of the stent in the delivery configuration.

[0011] Additionally or alternatively to any embodiment described herein, in a substantially inactive state, the adhesive structure has a thickness of about 0.254 mm to about 2.032 mm. In addition to or as an alternative to any of the embodiments described herein, a system for implanting a stent in a body lumen may include an elongate tubular member having a lumen extending therethrough, a stent configured to transition from a delivery configuration to a deployed configuration, and an adhesive structure configured to secure the stent to the body lumen in the deployed configuration. The stent may be disposed within the lumen of the elongate tubular member in the delivery configuration. The adhesive structure may be disposed within the lumen of the elongate tubular member adjacent to the stent in a substantially inactive state. The adhesive structure may be configured to adhere to the stent and the body lumen after the stent and adhesive structure are deployed from the lumen of the elongate tubular member into the body lumen. The adhesive structure may be disposed radially inward of the stent within the lumen of the elongate tubular member.

[0012] In addition or as an alternative to any of the embodiments described herein, after the stent and adhesive structure are deployed from the lumen of the elongated tubular member into the body lumen, the adhesive structure is configured to adhere to an inner surface of the stent, and the adhesive structure is configured to adhere to the body lumen through gaps formed in the stent.

[0013] In addition or as an alternative to any of the embodiments described herein, the adhesive structure includes a cross-linked polymer. In addition or as an alternative to any of the embodiments described herein, the adhesive structure includes a plurality of interwoven fibers that define a patch.

[0014] In addition, or as an alternative to any of the embodiments described herein, the adhesive structure extends longitudinally beyond at least one end of the stent. In addition to or in the alternative to any of the examples described herein, a method of securing a stent within a body lumen may include advancing an elongate tubular member having a stent and an adhesive structure retained therein to a target site within the body lumen, exposing the adhesive structure to the target site, deploying the stent at the target site to move the adhesive structure into contact with the target site, and applying a radially outward force to the adhesive structure for a predetermined period of time sufficient to adhere the adhesive structure to the stent and to the target site.

[0015] In addition or as an alternative to any of the embodiments described herein, an elongate inner member is disposed radially inward of the elongate tubular member to define an annular space, and the stent and adhesive structure are disposed within the annular space.

[0016] In addition to or in the alternative to any of the examples described herein, the method may further include injecting a fluid into the annular space to wet the adhesive structure when the adhesive structure is exposed to the target site.

[0017] In addition or as an alternative to any of the embodiments described herein, the adhesive structure may include an adhesive element, and the adhesive element may be activated by wetting the adhesive structure. Additionally or alternatively to any of the embodiments described herein, the stent is at least partially embedded within the adhesive structure by applying an outward radial force to the adhesive structure.

[0018] Additionally or alternatively to any of the embodiments described herein, the adhesive structure may be separate from the stent within the elongate tubular member. The above summary of some embodiments, aspects, and / or examples is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The following figures and detailed description more particularly exemplify these embodiments.

[0019] The present disclosure may be more fully understood from consideration of the following detailed description in conjunction with the accompanying drawings, in which: [Brief description of the drawings]

[0020] [Figure 1] 1A-1D illustrate selected aspects of a system for implanting a stent in a body lumen. [Diagram 2] FIG. 2 shows a cross-section of a portion of the system of FIG. 1. [Diagram 3] 2A-2D illustrate selected aspects associated with implantation of the stent of FIG. 1 within a body lumen. [Figure 4] 1A-1D illustrate selected aspects of a system for implanting a stent in a body lumen. [Diagram 5] FIG. 5 shows a cross-section of a portion of the system of FIG. 4. [Figure 6] 4A-4D illustrate selected aspects associated with implantation of the stent of FIG. 3 within a body lumen. [Figure 7] 1A-1D are cross-sectional views illustrating selected aspects of a stent according to the present disclosure implanted within a body lumen. [Figure 8] 1A-1D depict selected aspects of alternative configurations of the system and / or stent. [Figure 9] 1A-1D depict selected aspects of alternative configurations of the system and / or stent. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] While aspects of the present disclosure are amenable to various modifications and alternative forms, details thereof have been shown by way of example in the drawings and will be described in detail. It is to be understood, however, that the intention is not to limit aspects of the present disclosure to the particular embodiments described. On the contrary, the present invention is intended to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure.

[0022] The following description should be read with reference to the drawings, which are not necessarily to scale, but in which like reference numerals refer to like elements throughout the several views. The detailed description and drawings are intended to illustrate, rather than limit, the present disclosure. Those skilled in the art will recognize that the various elements described and / or illustrated can be arranged in various combinations and configurations without departing from the scope of the present disclosure. The detailed description and drawings show exemplary aspects of the present disclosure. However, for clarity and ease of understanding, not all features and / or elements may be shown in each drawing, although it can be understood that the features and / or elements are present unless otherwise specified.

[0023] For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification. In this specification, all numerical values ​​are assumed to be modified by the term "about", whether or not expressly indicated. The term "about" in the context of numerical values ​​generally refers to a range of numbers that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many cases, the term "about" may include numbers that are rounded to the nearest significant figure. Other uses of the term "about" (e.g., in non-numerical contexts) may be assumed to have their normal, customary definition as understood from and consistent with the context of this specification, unless otherwise specified.

[0024] The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5). Although some suitable dimensions, ranges and / or values ​​for various components, features and / or specifications are disclosed, one of ordinary skill in the art inspired by this disclosure will understand that the desired dimensions, ranges and / or values ​​may deviate from those expressly disclosed.

[0025] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term "or" is generally used in the sense of including "and / or," unless the content clearly dictates otherwise. For ease of understanding, it should be noted that some features of the present disclosure may be described in the singular even though those features may be multiple or repeated within the disclosed embodiment. Each instance of a feature may include and / or be encompassed by the singular disclosure unless expressly stated to the contrary. For simplicity and clarity, not all elements of the present disclosure are necessarily shown in each figure or described in detail below. It will be understood, however, that the following description may equally apply to any and / or all of the components present in more than one instance, unless expressly stated to the contrary.

[0026] Relative terms such as "proximal," "distal," "advance," "retract," and variations thereof may generally be considered with respect to the position, orientation, and / or movement of various elements relative to a user / operator / manipulator of the device, with "proximal" and "retract" indicating or referring to being closer to or toward the user, and "distal" and "advance" indicating or referring to being further from or away from the user. In some cases, the terms "proximal" and "distal" may be arbitrarily assigned to facilitate understanding of the present disclosure, and such cases will be readily apparent to those of ordinary skill in the art. Other relative terms such as "upstream," "downstream," "inflow," and "outflow" refer to the direction of fluid flow within a body lumen, lumen such as a blood vessel, or within a device. Still other relative terms such as "axial," "circumferential," "longitudinal," "lateral," "radial," and / or variations thereof generally refer to directions and / or orientations relative to a central longitudinal axis of the disclosed structure or device.

[0027] The term "range" can be understood to mean the maximum measurement of a stated or specified dimension, unless the range or dimension is prefaced with or specified as "minimum," which can be understood to mean the minimum measurement of the stated or specified dimension. For example, an "outer range" can be understood to mean an outer dimension, a "radial range" can be understood to mean a radial dimension, and a "longitudinal range" can be understood to mean a longitudinal dimension. Each instance of "range" can be different (e.g., axially, longitudinally, laterally, radially, circumferentially, etc.) and will be clear to one of ordinary skill in the art from the context of the particular use. In general, a "range" can be considered the maximum possible dimension measured according to the intended application, while a "minimum range" can be considered the minimum possible dimension measured according to the intended application. In some cases, a "range" can be generally measured orthogonally in a plane and / or cross section, but can also be measured differently, such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), as will be clear from the particular context.

[0028] The terms "monolithic" and "unitary" shall generally refer to one or more elements made up of or consisting of a single structure or base unit / element. Monolithic and / or unitary element shall exclude structures and / or features made up by assembling or otherwise joining together multiple separate structures or elements.

[0029] It should be noted that references herein to "one embodiment," "some embodiments," "other embodiments," and the like, indicate that the described embodiment may include a particular feature, structure, or characteristic, but that not all embodiments necessarily include the particular feature, structure, or characteristic. Moreover, such phrases do not necessarily refer to the same embodiment. Moreover, if a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one of ordinary skill in the art to use the particular feature, structure, or characteristic in connection with other embodiments, unless expressly stated to the contrary, whether or not explicitly described. That is, it is contemplated that various individual elements described below, even if not explicitly shown in a particular combination, can be combined or arranged with one another to form other additional embodiments or to complement and / or enhance the described embodiments, as would be understood by one of ordinary skill in the art.

[0030] For purposes of clarity, certain distinguishing numerical nomenclature (e.g., first, second, third, fourth, etc.) may be used throughout the specification and / or claims to name and / or distinguish various features of the specification and / or claims. It should be understood that the numerical nomenclature is not intended to be limiting, but is merely exemplary. In some embodiments, modifications and departures from previously used numerical nomenclature may be made for brevity and clarity. That is, a feature identified as a "first" element may later be referred to as a "second" element, a "third" element, etc., or may be omitted entirely, and / or a different feature may be referred to as the "first" element. The meaning and / or name in each instance will be apparent to one of ordinary skill in the art.

[0031] The figures show selected components and / or arrangements of an endoprosthesis or stent. It should be noted that in any given figure, some features of an endoprosthesis or stent may not be shown or may be shown in schematic form for simplicity. Further details regarding some of the components of an endoprosthesis or stent may be shown in more detail in other figures. It should be noted that for ease of understanding, some features of the present disclosure may be described in the singular even though those features may be multiple or repeated within the disclosed embodiment. Each instance of a feature may include and / or be encompassed by the singular disclosure unless expressly stated to the contrary. For example, reference to a "filament," "cell," "strut," or other feature may equally refer to all instances and quantities of more than one of that feature. Thus, it will be understood that the following description may equally apply to any and / or all of the components present in more than one endoprosthesis or stent unless expressly stated to the contrary. Moreover, for clarity, not all instances of some elements or features are shown in every figure.

[0032] 1-3 illustrate selected aspects of a stent delivery system 100 designed and configured for delivery and / or implantation of a stent 130 into a body lumen 10. The term "stent" may be used interchangeably herein with the term "endoprosthesis." The system 100 may include an elongated tubular member 110 (e.g., an outer tubular member) having a lumen 112 extending therein and / or therethrough. In some alternative embodiments, the elongated tubular member 110 may include multiple lumens extending therein and / or therethrough. In at least some embodiments, the system 100 may include an elongated inner member 120 disposed within the lumen 112 of the elongated tubular member 110. In some embodiments, the elongated inner member 120 may be a tubular member having a lumen 122 extending therein and / or therethrough. In some embodiments, the lumen 122 of the elongated inner member 120 may be a guidewire lumen. In some embodiments, the lumen 122 of the elongate inner member 120 may be used for irrigation and / or aspiration. Other configurations are envisioned. In some alternative embodiments, the elongate inner member 120 may be a solid shaft.

[0033] In some embodiments, the elongate inner member 120 may be capable of moving axially relative to the elongate tubular member 110. In some embodiments, the elongate tubular member 110 may be capable of moving proximally relative to the elongate inner member 120. For example, the elongate inner member 120 may be held in a fixed position while the elongate tubular member 110 is withdrawn proximally. In some embodiments, the elongate tubular member 110 and the elongate inner member 120 may be configured to be advanced together and / or simultaneously to a target site. In at least some embodiments, the elongate tubular member 110 and the elongate inner member 120 may be disposed and / or held in an axially fixed relationship relative to one another during advancement to a target site. Other configurations are envisioned.

[0034] In some embodiments, the system 100 can include a stent 130. The stent 130 can include a tubular scaffold extending along a central longitudinal axis and defining a length from a proximal end to a distal end. The stent 130 and / or the tubular scaffold can be configured to transition between a delivery configuration (e.g., a radially collapsed configuration as seen in FIG. 1 ) and a deployed configuration (e.g., a radially expanded configuration as seen in FIG. 3 ). The delivery configuration can be a configuration in which the stent 130 is axially elongated and / or radially collapsed or compressed as compared to the deployed configuration. The deployed configuration can be a configuration in which the stent 130 is axially shortened and / or radially expanded as compared to the delivery configuration.

[0035] In some embodiments, the stent 130 may be disposed within the lumen 112 of the elongate tubular member 110 in the delivery configuration. In some embodiments, the elongate tubular member 110 may constrain the stent 130 in the delivery configuration when the stent 130 is disposed within the lumen 112 of the elongate tubular member 110. In some embodiments, the stent 130 may be radially disposed between the elongate tubular member 110 and the elongate inner member 120. In some embodiments, the stent 130 may be attached to, crimped onto, and / or otherwise retained by the elongate inner member 120. Other configurations are also envisioned.

[0036] In some embodiments, the stent 130 or tubular scaffold can be self-expandable. For example, the stent 130 or tubular scaffold can be formed from a superelastic and / or shape memory material. In some embodiments, the stent 130 or tubular scaffold can be mechanically expandable. In some embodiments, the elongate inner member 120 can include an expandable member 124 (e.g., FIG. 6), such as an inflatable balloon, a mechanical expansion member, an actuation member, or the like, configured to transition the stent 130 or tubular scaffold from a delivery configuration to a deployed configuration.

[0037] During delivery to a treatment site, the stent 130 and / or tubular scaffolding may be disposed within the lumen 112 of the elongate tubular member 110 in a delivery configuration. Upon removal and / or release of the elongate tubular member 110 from the lumen 112, the stent 130 and / or tubular scaffolding may and / or can transition from the delivery configuration to a deployed configuration.

[0038] A stent 130 or tubular scaffold may include and / or be formed of multiple cells. In some embodiments, a stent 130 or tubular scaffold may include and / or be formed from one or more filaments interwoven about a central longitudinal axis of the stent 130 or tubular scaffold. In at least some embodiments, the one or more filaments may form and / or define multiple cells. In some embodiments, a stent 130 or tubular scaffold may be braided, knitted, or woven from one or more filaments. In some embodiments, the one or more filaments may include wire(s), thread(s), strand(s), etc. In some embodiments, the one or more filaments may define gaps 132 (e.g., openings) formed in and / or through the wall of the stent 130 or tubular scaffold. Alternatively, in some embodiments, the stent 130 or tubular scaffold may be a monolithic structure formed from a cylindrical tubular member, such as a single cylindrical laser cut tubular member. The remaining (e.g., not removed) portion of the tubular member forms the stent 130 or tubular scaffold, with interstices 132 formed in and / or through the wall of the stent 130 or tubular scaffold. In yet another alternative, the stent 130 or tubular scaffold may be formed from a flat sheet of material having interstices 132 formed therein, which is then rolled and fixed into a tubular shape. Other configurations are envisioned.

[0039] The stent 130 or tubular scaffold may be substantially tubular and / or may include a lumen extending axially therethrough along a central longitudinal axis of the stent 130 or tubular scaffold. In some embodiments, the stent 130 or tubular scaffold may have an axial length of about 20 millimeters to about 250 millimeters, about 40 millimeters to about 225 millimeters, about 60 millimeters to about 200 millimeters, about 80 millimeters to about 175 millimeters, about 100 millimeters to about 150 millimeters, or another suitable range. In some embodiments, the stent 130 or tubular scaffold may have an outer radial dimension or radial range of about 4 millimeters to about 30 millimeters, about 6 millimeters to about 25 millimeters, about 8 millimeters to about 20 millimeters, about 10 millimeters to about 15 millimeters, or another suitable range. Other configurations are contemplated. Some suitable, but non-limiting, materials for the stent 130, tubular scaffold, and / or components or elements thereof, such as metallic and / or polymeric materials, are described below.

[0040] In some embodiments, the stent 130 or tubular scaffold may include a polymeric covering extending along the tubular scaffold. In some embodiments, the polymeric covering may be secured, bonded, or otherwise attached along and / or around the circumference of the tubular scaffold. In some embodiments, the polymeric covering may be secured, bonded, or otherwise attached to the tubular scaffold at least some locations where the polymeric covering contacts the tubular scaffold. In some embodiments, the polymeric covering may be secured, bonded, or otherwise attached to the tubular scaffold at any and all locations where the polymeric covering contacts the tubular scaffold. In some embodiments, the tubular scaffold or portions thereof may be embedded within the polymeric covering. Other configurations are envisioned.

[0041] In some embodiments, the polymer coating may extend along the entire length of the stent 130 or tubular scaffold. In some embodiments, the polymer coating may extend along a portion of the length of the stent 130 or tubular scaffold. In some embodiments, the polymer coating may extend discontinuously between the proximal end of the stent 130 or tubular scaffold and the distal end of the stent 130 or tubular scaffold. In some embodiments, the polymer coating may extend continuously from the proximal end of the stent 130 or tubular scaffold to the distal end of the stent 130 or tubular scaffold. Other configurations are also envisioned. Some suitable examples of materials for the polymer coating are described below, including, but not limited to, PTFE, silicone, and the like.

[0042] In some embodiments, the system 100 may include an adhesive structure 140 configured to secure the stent 130 or tubular scaffold to the body lumen 10 in a deployed configuration. In some embodiments, the adhesive structure 140 may be formed from a polymeric material. In some embodiments, the adhesive structure 140 may include a cross-linked polymer. In some embodiments, the adhesive structure 140 may include a plurality of interwoven fibers 142 (e.g., detailed view of FIG. 1 ), which may optionally form a fibrous patch. In some embodiments, the plurality of interwoven fibers 142 may include and / or be formed from a polymeric material or a plurality of polymeric materials. In some embodiments, the interwoven fibers of the adhesive structure 140 may have a braided, woven, knitted, cross-knitted, randomly oriented, or porous configuration. In some embodiments, the adhesive structure 140 may include perforations, pores, and / or a plurality of small openings disposed therein.

[0043] The elongate inner member 120 may be disposed radially inward of the elongate tubular member 110 within the lumen 112 of the elongate tubular member 110 to define an annular space 114. The adhesive structure 140 may be disposed within the lumen 112 of the elongate tubular member 110 adjacent the stent 130 and the tubular scaffold in a substantially inactive state. In at least some embodiments, the stent 130 and adhesive structure 140 may be disposed within the annular space 114 defined by the elongate inner member 120 and the elongate tubular member 110 in a delivery configuration and / or in a substantially inactive state.

[0044] In some embodiments, the adhesive structure 140 may take the form of a fibrous patch. The adhesive structure 140 may not be secured to the stent 130 or tubular scaffold within the lumen 112 of the elongate tubular member 110. Alternatively, the adhesive structure 140 may not be secured to the stent 130 or tubular scaffold within the annular space 114 and / or in a substantially inactive state. In some embodiments, the adhesive structure 140 may be separated from the stent 130 or tubular scaffold within the lumen 112 of the elongate tubular member 110, within the annular space 114 and / or in a substantially inactive state. As referred to herein, unsecured or separated from the stent 130 means that the adhesive structure 140 is in contact with the stent 130 but there is no bond or connection between the adhesive structure 140 and the stent 130 while disposed against the stent 130 in its inactive state. In some embodiments, the adhesive structure 140 may extend circumferentially around a majority of the circumference of the stent 130 or tubular scaffold in the delivery configuration and / or within the annular space 114. In some embodiments, the adhesive structure 140 may extend longitudinally along the length of the stent 130 or tubular scaffold. In some embodiments, the adhesive structure 140 may extend longitudinally along a majority of the length of the stent 130 or tubular scaffold. In some embodiments, the adhesive structure 140 may extend longitudinally along the entire length of the stent 130 or tubular scaffold. In some embodiments, in a substantially inactive state, the adhesive structure 140 can have a thickness of about 0.100 millimeters (mm) to about 2.750 mm, about 0.150 mm to about 2.500 mm, about 0.200 mm to about 2.250 mm, about 0.250 mm to about 2.000 mm, about 0.500 mm to about 1.750 mm, about 0.750 mm to about 1.500 mm, etc.

[0045] In some embodiments, the adhesive structure 140 can be configured to adhere to the stent 130, tubular scaffolding, and body lumen 10 after the stent 130, tubular scaffolding, and adhesive structure 140 are deployed from the lumen 112 of the elongate tubular member 110 into the body lumen 10. In some embodiments, the adhesive structure 140 can include adhesive elements that can be activated upon deployment in the body lumen 10. In some embodiments, the adhesive elements can extend continuously along the adhesive structure 140. In some embodiments, the adhesive elements can extend continuously along the entire length of the adhesive structure 140. In some embodiments, the adhesive elements can extend discontinuously along the adhesive structure 140. Other configurations are also envisioned.

[0046] In some embodiments, the adhesive element and / or adhesive structure 140 may include a bioadhesive material. In some embodiments, the bioadhesive material may include natural polymeric materials, as well as synthetic materials and synthetic materials formed from biological monomers such as sugars. In some embodiments, the bioadhesive may be obtained from the secretions of microorganisms or by marine mollusks and crustaceans. In some embodiments, the bioadhesive is designed to adhere to biological tissue. Some examples of bioadhesives may include, but are not limited to, mucoadhesives, aminoadhesives, adhesive surface proteins, adhesive modified polymers, catechol moieties, polymeric materials, polysaccharides, hydrogels, crosslinked or non-crosslinked minigel particles, and the like, as well as mixtures and / or combinations thereof.

[0047] In at least some embodiments, the term "substantially inactive state" may include and / or refer to the adhesive structure 140, which may be non-reactive to adjacent elements of the system 100 and / or body lumen 10, or may exhibit non-adhesive properties to adjacent elements of the system 100 and / or body lumen 10, or both. For example, in a substantially inactive state, the adhesive structure 140 may not adhere to the stent 130, the elongate inner member 120, and / or the elongate tubular member 110. Additionally, in a substantially inactive state, the adhesive structure 140 may not adhere to the body lumen 10. In some embodiments, in a substantially inactive state, the adhesive structure 140 may be substantially dry, dehydrated, or devoid of moisture. In some embodiments, the adhesive elements associated with the adhesive structure 140 may be activated by adding or introducing fluid(s), moisture, and / or a selected type of fluid to the adhesive structure 140. In situations and / or configurations in which the adhesive structure 140 and / or adhesive elements become "sticky," "tacky," etc., relative to adjacent structures and / or elements, the adhesive structure 140 can be assumed to no longer be in a substantially inactive state.

[0048] In some embodiments, the adhesive structure 140 can include a first longitudinal edge 144 and a second longitudinal edge 146 opposite the first longitudinal edge 144. The first longitudinal edge 144 and the second longitudinal edge 146 can be oriented substantially parallel to a central longitudinal axis of the stent 130 or tubular scaffold. The first longitudinal edge 144 can be disposed adjacent to the second longitudinal edge 146 in a delivery configuration and / or when the adhesive structure 140 is disposed within the lumen 112 of the elongate tubular member 110 and / or when the adhesive structure 140 is disposed within the annular space 114. In at least some embodiments, in the delivery configuration and / or when the adhesive structure 140 is disposed within the lumen 112 of the elongate tubular member 110 and / or when the adhesive structure 140 is disposed within the annular space 114, the first longitudinal edge 144 can extend generally parallel to and spaced apart from the second longitudinal edge 146 to define a longitudinal gap 148 between the first longitudinal edge 144 and the second longitudinal edge 146. In some embodiments, the adhesive structure 140 can be free of circumferential overlap between the first longitudinal edge 144 and the second longitudinal edge 146 (e.g., in a circumferential arc about the central longitudinal axis of the stent 130). Circumferential overlap between the first longitudinal edge 144 and the second longitudinal edge 146 within the lumen 112 of the elongated tubular member 110 and / or circumferential overlap between the first longitudinal edge 144 and the second longitudinal edge 146 within the annular space 114 may cause pinching and / or bonding of the stent 130 and the adhesive structure 140 in an undesirable manner within and / or relative to the elongated inner member 120 and the elongated tubular member 110, thereby making deployment of the stent 130 and the adhesive structure 140 more difficult and / or increasing the likelihood or likelihood of damage to the system 100 and / or its components.

[0049] In some embodiments, the first longitudinal edge 144 and the second longitudinal edge 146 may be further apart (e.g., the longitudinal gap 148 may be wider) in the deployed configuration and / or when the adhesive structure 140 is disposed within the body lumen 10 than in the delivery configuration and / or when the adhesive structure 140 is disposed within the lumen 112 and / or the annular space 114 of the elongate tubular member 110.

[0050] In some embodiments, the adhesive elements can be activated by wetting the adhesive structure 140 with a fluid. In other examples, the adhesive elements can be activated by another stimulus. In at least some embodiments, the adhesive elements can be pressure sensitive. In some embodiments, the adhesive structure 140 can be disposed radially outward of the stent 130 or tubular scaffold within the lumen 112 of the elongated tubular member 110, as seen in FIGS. 1-2. In some embodiments, the entire adhesive structure 140 can be disposed radially outward of the stent 130 or tubular scaffold within the lumen 112 of the elongated tubular member 110. In some embodiments, after the stent 130 and adhesive structure 140 are deployed within the body lumen 10, the adhesive structure 140 can be disposed substantially radially outward of the stent 130 or tubular scaffold, as seen in FIG. 3. In some embodiments, the adhesive structure 140 may be disposed entirely radially outward of the stent 130 and tubular scaffold after the stent 130 and adhesive structure 140 are deployed within the body lumen 10. Other configurations are envisioned. Thus, a radially outward expansive force exerted by the stent 130 on the adhesive structure 140 may activate the pressure sensitive adhesive.

[0051] In some embodiments, a method of securing the stent 130 within the body lumen 10 may include exposing the adhesive structure 140 to a target site within the body lumen 10 and / or deploying the adhesive structure 140 to the target site within the body lumen 10. In some embodiments, the system 100 may include a fluid source that may be in fluid communication with the lumen 112 of the elongate tubular member 110 and / or the annular space 114 between the elongate tubular member 110 and the elongate inner member 120. In some embodiments, a fluid may be injected into the annular space 114 and / or the longitudinal gap 148 when the adhesive structure 140 is exposed to the target site and / or when the adhesive structure 140 is deployed from the lumen 112 of the elongate tubular member 110. In some embodiments, a fluid (e.g., saline) injected into the annular space 114 and / or longitudinal gap 148 may wet the adhesive structure 140 and / or activate the adhesive elements when the adhesive structure 140 is exposed to a target site within the body lumen 10 and / or when the adhesive structure 140 is deployed from the lumen 112 of the elongate tubular member 110. In some embodiments, fluids (e.g., bodily fluids, blood, mucus, etc.) present within the body lumen 10 may wet or assist in wetting the adhesive structure 140.

[0052] Because the stent 130 can be securely held in a radially contracted state within the elongated tubular member 110, the presence of a longitudinal gap 148 extending along the length of the adhesive structure 140 can allow fluid to flow along the longitudinal gap 148 to reach the distal end of the adhesive structure 140 while the stent 130 and adhesive structure are restrained within the lumen of the elongated tubular member 110.

[0053] In some embodiments, a method of securing the stent 130 within the body lumen 10 may include deploying the stent 130 at a target site within the body lumen 10. In some embodiments, after the stent 130 and / or the tubular scaffold and the adhesive structure 140 are deployed within the body lumen 10, the stent 130 may be transitioned to a deployed configuration such that the stent 130 and / or the tubular scaffold exerts a radially outward force against the adhesive structure 140 and the body lumen 10, as seen in FIG. 3. In some embodiments, deploying the stent 130 at a target site within the body lumen 10 and / or transitioning the stent 130 to a deployed configuration may move the adhesive structure 140 into contact with the target site and / or the body lumen 10. In some embodiments, a method of securing the stent 130 within the body lumen 10 may include applying a radially outward force to the adhesive structure 140 for a predetermined period of time sufficient to adhere the adhesive structure to the stent 130 and the target site (e.g., the body lumen 10). In some embodiments, after the stent 130 and adhesive structure 140 are deployed from the lumen 112 of the elongated tubular member 110 into the body lumen 10, the adhesive structure 140 can be configured to adhere to an outer surface of the stent 130 and / or the adhesive structure 140 can be configured to adhere to the body lumen 10.

[0054] In some embodiments, the radially outward force can strengthen the adhesion between the stent 130 or tubular scaffold and the adhesive structure 140, and the radially outward force can increase the adhesion between the adhesive structure 140 and the body lumen 10. In some embodiments, the radially outward force can be applied to the adhesive structure 140 and / or the body lumen 10 for a period of time to allow the adhesive elements to cure and / or to allow cross-linking to occur between the adhesive structure 140 and the adhesive elements. In some embodiments, after the adhesive elements cure and / or after cross-linking occurs between the adhesive structure 140 and the adhesive elements, the adhesive structure 140 can be permanently adhered to the target site within the stent 130 and / or the body lumen 10.

[0055] Figures 4-6 illustrate selected aspects of alternative configurations of the system 100 described herein. Except as expressly described herein with respect to Figures 4-6, the system 100 may be configured and / or function as described above with respect to Figures 1-3.

[0056] In some embodiments, the elongate inner member 120 can include an expandable member 124. The stent 130 and / or adhesive structure 140 can be disposed radially outward of the elongate inner member 120 and the expandable member 124. In some embodiments, the stent 130 and / or adhesive structure 140 can be disposed directly on the expandable member 124. The adhesive structure 140 can be disposed radially inward of the stent 130 or tubular scaffold within the lumen 112 of the elongate tubular member 110 and / or the adhesive structure 140 can be disposed radially inward of the stent 130 or tubular scaffold within the annular space 114 defined by the elongate inner member 120 and the elongate tubular member 110, as seen in FIGS. 4-5 .

[0057] In some embodiments, after exposing the adhesive structure 140 to the target site and / or body lumen 10, a method of securing the stent 130 within the body lumen 10 may include deploying the stent 130 at the target site and moving the adhesive structure 140 into contact with the target site and / or body lumen 10. In some embodiments, the expandable member 124 can be configured to move the adhesive structure 140 into contact with the inner surface of the stent 130 or tubular scaffold when transitioned from a delivery configuration to an expanded configuration, as seen in FIG. 6. In some embodiments, the expandable member 124 can be configured to move the adhesive structure 140 into contact with the target site and / or body lumen 10 when transitioned from a delivery configuration to an expanded configuration.

[0058] In some embodiments, after the stent 130 and adhesive structure 140 are deployed in the body lumen 10, the adhesive structure 140 may be disposed substantially radially inward of the stent 130 or tubular scaffold. In some embodiments, after the stent 130 and adhesive structure 140 are deployed in the body lumen 10 and after the stent 130 is transitioned to a deployed configuration, at least a portion of the adhesive structure 140 may protrude into and / or through the gaps 132 formed in the wall of the stent 130 or tubular scaffold. In some embodiments, after the stent 130 is transitioned to a deployed configuration and the expandable member 124 is transitioned to an expanded configuration, at least a portion of the adhesive structure 140 may protrude into and / or through the gaps 132 formed in the wall of the stent 130 or tubular scaffold to contact the body lumen 10.

[0059] In some embodiments, the adhesive structure 140 can be configured to adhere to the stent 130 or tubular scaffold and the body lumen 10 after the stent 130 or tubular scaffold and the adhesive structure 140 are deployed into the body lumen 10 from the lumen 112 of the elongate tubular member 110. In some embodiments, the adhesive structure 140 can be configured to adhere to an inner surface of the stent 130 after the stent 130 and the adhesive structure 140 are deployed into the body lumen 10 from the lumen 112 of the elongate tubular member 110, and the adhesive structure 140 can be configured to adhere to the body lumen 10 through gaps 132 formed in the wall of the stent 130 or tubular scaffold.

[0060] In some cases, the expandable member 124 (e.g., an inflatable balloon) may include a plurality of pores or apertures that allow fluid from inside the expandable member 124 to seep through the sidewall of the expandable member 124 and directly contact the adhesive structure 140, wetting the adhesive structure 140 during deployment and thus activating the adhesive elements of the adhesive structure 140.

[0061] FIG. 7 illustrates selected aspects of the stent 130 and / or adhesive structure 140 after deployment within the body lumen 10. At least some aspects seen in FIG. 7 may occur and / or be present in the embodiment(s) of FIGS. 1-6. In some embodiments, the stent 130 or tubular scaffold is at least partially embedded within the adhesive structure 140 by applying an outward radial force to the adhesive structure 140 and / or stent 130 as described herein. In some embodiments, the adhesive structure 140 may be softened by wetting the adhesive structure 140. In some embodiments, after wetting the adhesive structure 140 and / or applying an outward radial force to the adhesive structure 140 and / or stent 130 of FIGS. 1-3, the stent 130 or tubular scaffold may be pressed and / or urged into the adhesive structure 140 to at least partially embed the stent 130 or tubular scaffold within the adhesive structure 140. In some embodiments, after wetting the adhesive structure 140 and / or applying an outward radial force to the adhesive structure 140 and / or the stent 130 of Figures 4-6, the adhesive structure 140 can be forced through and / or around the stent 130 or tubular scaffold to at least partially embed the stent 130 or tubular scaffold within the adhesive structure 140. Other configurations are contemplated.

[0062] FIG. 8 illustrates selected aspects of alternative configurations of the system 100. In some embodiments, the adhesive structure 140 may comprise and / or include multiple distinct regions disposed along the length of the stent 130 or tubular scaffold. In some embodiments, the multiple distinct regions may be spaced apart from one another along the length of the stent 130. In some embodiments, the multiple distinct regions may be regularly spaced apart (e.g., arranged in a defined pattern) along the length of the stent 130. In some embodiments, the multiple distinct regions may be irregularly spaced apart (e.g., randomly spaced) along the length of the stent 130. In some embodiments, the multiple distinct regions may be disposed along and / or on the exterior surface of the stent 130, similar to the embodiment(s) shown in FIGS. 1-3. In some embodiments, the multiple distinct regions may be disposed along and / or against the interior surface of the stent 130, similar to the embodiment(s) shown in FIGS. 4-6. Other configurations, including various combinations thereof, are also envisioned.

[0063] 9 illustrates selected aspects of alternative configurations of the system 100. In some embodiments, the adhesive structure 140 may extend longitudinally beyond at least one end of the stent 130. For example, the adhesive structure 140 may be disposed at a distal end of the stent 130 and may extend distally beyond the distal end of the stent 130. Additionally or alternatively, the adhesive structure 140 may be disposed at a proximal end of the stent and extend proximally beyond the proximal end of the stent 130. In some cases, the adhesive structure 140 extending beyond the proximal and / or distal ends of the stent 130 may be a cuff that extends entirely around the circumference of the end of the stent 130. In some embodiments, the adhesive structure 140 may comprise and / or include multiple distinct regions or strips disposed at at least one end of the stent 130 or tubular scaffold and / or immediately adjacent to the stent 130 or tubular scaffold. In some embodiments, the multiple distinct regions or strips may be circumferentially spaced around the circumference of the stent 130. In some embodiments, the multiple distinct regions or strips may be regularly spaced around the circumference of the stent 130 (e.g., arranged in a defined pattern). In some embodiments, the multiple distinct regions or strips may be irregularly spaced around the circumference of the stent 130 (e.g., randomly arranged). In some embodiments, the multiple distinct regions or strips may be disposed along and / or on the outer surface of the stent 130, similar to the embodiment(s) shown in Figures 1-3. In some embodiments, the multiple distinct regions or strips may be disposed along and / or against the inner surface of the stent 130, similar to the embodiment(s) shown in Figures 4-6. Other configurations, including various combinations thereof, are also envisioned. In one embodiment, the expandable member 124 of the elongate inner member 120 can be configured to apply a radially outward force to the adhesive structure 140 (e.g., multiple distinct regions) and / or the stent 130 to move the adhesive structure 140 (e.g., multiple distinct regions) and / or the stent 130 into contact with the body lumen 10.

[0064] The various components of the systems disclosed herein and materials that can be used for the various elements thereof may include those commonly associated with medical devices. For purposes of simplicity, the following description refers to systems. However, this is not intended to limit the systems, devices, and / or methods described herein, and the description may apply to other elements, members, components, or devices disclosed herein, such as, but not limited to, elongated tubular members, elongated inner members, stents, tubular scaffolds, polymeric coatings, adhesive structures, and / or elements or components thereof.

[0065] In some embodiments, the system and / or its components may be made from metals, metal alloys, polymers (some examples of which are disclosed below), metal-polymer composites, ceramics, combinations thereof, or the like, or other suitable materials.

[0066] Some examples of suitable polymers include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, e.g., DELRIN®), polyether block esters, polyurethanes (e.g., Polyurethane 85A), polypropylene (PP), polyvinyl chloride (PVC), polyether esters (e.g., ARNITEL®), ether or ester based copolymers (e.g., butylene / poly(alkylene ether) phthalates, and / or other polyester elastomers such as HYTREL®), polyamides (e.g., DURETHAN® or CRISTAMID®), elastomeric polyamides, block polyamide / ethers, polyether block amides (PEBA, available, for example, under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), MARLEX® high density polyethylene, MARLEX® low density polyethylene, linear low density polyethylene (e.g., REXELL®), ... (registered trademark)), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyether ether ketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), polyparaphenylene terephthalamide (e.g., KEVLAR®), polysulfone, nylon, nylon-12 (e.g., GRILAMID®), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (e.g., SIBS and / or SIBS 50A), polycarbonate, polyurethane silicone copolymers (e.g., Elast-Eon® or ChronoSil®), biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers, polymer / metal composites, and the like.In some embodiments, the system and / or its components can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6% LCP.

[0067] Some examples of suitable metals and metal alloys include stainless steels, such as 304V, 304L, and 316LV stainless steels; mild steels; nickel-titanium alloys, such as linear elastic and / or superelastic Nitinol; other nickel alloys, such as nickel-chromium-molybdenum alloys (e.g., UNS:N06625, such as INCONEL® 625; UNS:N06022, such as HASTELLOY® C-22®; HASTELLOY® C276®); (UNS:N10276 such as HASTELLOY® alloys, other HASTELLOY® alloys, etc.), nickel-copper alloys (e.g., UNS:N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, etc.), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS:R30035 such as MP35-N®), nickel-molybdenum alloys (e.g., HASTELLOY® ALLOY® alloys, other HASTELLOY® alloys, etc.), nickel-cobalt alloys (e.g., UNS:N10276 such as HASTELLOY® alloys, other HASTELLOY® alloys, B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, cobalt-chromium alloys, cobalt-chromium-molybdenum alloys (e.g., UNS:R30003, such as ELGILOY®, PHYNOX®), platinum-rich stainless steels, titanium, platinum, palladium, gold, combinations thereof, or any other suitable material.

[0068] In some embodiments, the linear elastic and / or non-superelastic nickel-titanium alloy may range from about 50 to about 60 weight percent nickel. The remainder is essentially titanium. In some embodiments, the composition ranges from about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy, available from Furukawa Techno Material Co., Ltd., Kanagawa, Japan. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, such as superelastic Nitinol, may be used to achieve the desired properties.

[0069] In at least some embodiments, some or all of the system and / or its components may also be doped with, made of, or otherwise include radiopaque materials. A radiopaque material is understood to be a material that can produce a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the system in determining its location. Some examples of radiopaque materials include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloys, polymeric materials loaded with radiopaque fillers, and the like. Additionally, other radiopaque marker bands and / or coils may also be incorporated into the design of the system to achieve the same results.

[0070] In some embodiments, a degree of Magnetic Resonance Imaging (MRI) compatibility is imparted to the systems and / or other elements disclosed herein. For example, the systems and / or components or portions thereof can be made of materials that do not substantially distort the image and do not cause substantial artifacts (i.e., gaps in the image). For example, certain ferromagnetic materials may not be suitable because they may cause artifacts in the MRI image. The systems or portions thereof may also be made of materials that MRI machines can image. Some materials that exhibit these properties include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS:R30003, such as ELGILOY®, PHYNOX®, etc.), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS:R30035, such as MP35-N®), nitinol, etc., and others.

[0071] In some embodiments, the systems and / or other elements disclosed herein may include a woven material disposed on or within the structure. The woven material may be comprised of a biocompatible material, such as a polymeric material or a biomaterial, adapted to promote tissue ingrowth. In some embodiments, the woven material may include a bioabsorbable material. Some examples of suitable woven materials include, but are not limited to, polyethylene glycol (PEG), nylon, polytetrafluoroethylene (PTFE), ePTFE), polyolefin-based materials such as polyethylene, polypropylene, polyester, polyurethane, and / or blends or combinations thereof.

[0072] In some embodiments, the systems and / or other elements disclosed herein may include and / or be formed from textile materials. Some examples of suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk, or unshrunk. Synthetic biocompatible yarns suitable for use in the present disclosure include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylene, polyethylene, polyurethanes, polyolefins, polyvinyls, polymethylacetates, polyamides, naphthalene dicarboxylic acid derivatives, natural silk, and polytetrafluoroethylene. Furthermore, at least one of the synthetic yarns may be a metal yarn, a glass or ceramic yarn, or a fiber. Useful metal yarns include yarns made from or containing stainless steel, platinum, gold, titanium, tantalum, or Ni-Co-Cr based alloys. The yarns may further include carbon fibers, glass fibers, or ceramic fibers. Desirably, the threads are made from thermoplastic materials, including but not limited to polyester, polypropylene, polyethylene, polyurethane, polynaphthalene, polytetrafluoroethylene, and the like. The threads may be of the multifilament, monofilament, or spun type. The type and denier of the thread selected may be selected to form a biocompatible and implantable prosthesis, and more particularly, a vascular structure, having desirable properties.

[0073] In some embodiments, the systems and / or other elements disclosed herein may include and / or be treated with a suitable therapeutic agent. Some examples of suitable therapeutic agents include antithrombotic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyl ketone)); antiproliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antitumor / antiproliferative / antimitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anticoagulants (such as D-Phe-Pro-Arg chloromethylketone, RGD peptide-containing compounds, heparin, antithrombin compounds, platelet receptor antagonists, antithrombin antibodies, antiplatelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptide); vascular cell growth promoters (such as growth factor inhibitors, growth factor receptor antagonists, transcription activators, and translation promoters); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcription repressors, translation repressors, replication inhibitors, inhibitory antibodies, antibodies against growth factors, bifunctional molecules consisting of growth factors and cytotoxins, bifunctional molecules consisting of antibodies and cytotoxins); cholesterol lowering agents; vasodilators; and agents that interfere with endogenous vasoactive mechanisms.

[0074] It will be understood that the present disclosure is in many respects merely illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps, without exceeding the scope of the present disclosure. This may include, to the extent appropriate, using any of the features of one exemplary embodiment in other embodiments. The scope of the present disclosure is, of course, defined in the language in which the appended claims are expressed.

Claims

1. 1. A system for implanting a stent in a body lumen, comprising: an elongated tubular member having a lumen extending therethrough; a stent configured to transition from a delivery configuration to a deployed configuration; an adhesive structure configured to secure the stent to the body lumen in the deployed configuration; Equipped with the stent is disposed within the lumen of the elongate tubular member in the delivery configuration; the adhesive structure is disposed in a substantially inactive state within the lumen of the elongate tubular member adjacent to the stent; the adhesive structure is configured to adhere to the stent and the body lumen after the stent and the adhesive structure are deployed from the lumen of the elongate tubular member into the body lumen. system.

2. The system of claim 1 , wherein the adhesive structure is unsecured to the stent within the lumen of the elongate tubular member.

3. The system of claim 1 or 2, wherein the adhesive structure comprises adhesive elements that are activated upon deployment within the body lumen.

4. The system of claim 3 , wherein the adhesive element is pressure sensitive.

5. The system of any one of claims 1 to 4, wherein the adhesive structure is disposed within the lumen of the elongate tubular member radially outward of the stent.

6. The system of any one of claims 1 to 5, wherein the stent exerts a radially outward force on the adhesive structure and the body lumen after the stent and the adhesive structure are deployed within the body lumen.

7. The system of claim 6 , wherein the outward radial force enhances adhesion between the stent and the adhesive structure and between the adhesive structure and the body lumen.

8. The system of any one of claims 1 to 7, wherein the adhesive structure extends circumferentially around a majority of the circumference of the stent in the delivery configuration.

9. The system of any one of claims 1 to 8, wherein in the substantially inactive state, the adhesive structure has a thickness of between about 0.254 mm and about 2.032 mm.

10. The system of any one of claims 1 to 4, wherein the adhesive structure is disposed within the lumen of the elongate tubular member radially inward of the stent.

11. 11. The system of claim 10, wherein the adhesive structure is configured to adhere to an inner surface of the stent after the stent and the adhesive structure are deployed from the lumen of the elongated tubular member into the body lumen, and the adhesive structure is configured to adhere to the body lumen through gaps formed in the stent.

12. The system of any one of claims 1 to 11, wherein the adhesive structure comprises a cross-linked polymer.

13. The system of any one of claims 1 to 12, wherein the adhesive structure comprises a plurality of interwoven fibers defining a patch.

14. 12. The system of claim 10 or 11, wherein the adhesive structure extends longitudinally beyond at least one end of the stent.

15. 1. A method for anchoring a stent in a body lumen, comprising: advancing an elongate tubular member having a stent and an adhesion structure retained therein to a target site within the body lumen; exposing the adhesive structure to the target site; deploying the stent at the target site to move the adhesive structure into contact with the target site; applying an outward radial force to the adhesive structure for a predetermined period of time sufficient to adhere the adhesive structure to the stent and to the target site; A method comprising:

Images